Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	0.07 -	0.20 176.76%	4.47 2,154.23%	6.49 45.20%	5.09 21.57%	3.81 25.11%
company equity multiplier	-2.23 -	1.52 168.13%	1.03 31.95%	1.03 0.03%	1.05 1.62%	1.07 1.62%
days of inventory outstanding
days of payables outstanding						5.23K -
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	1 -	1 0%	1 0%	0.98 1.81%	0.99 0.63%	0.89 9.64%
effective tax rate	-0.00 -			0.01 -	0.01 120.55%	0.00 100.00%
enterprise value multiple	-53.58 -	-37.80 29.46%	-10.80 71.44%	-2.84 73.72%	-1.97 30.62%	-1.40 29.11%
fixed asset turnover
free cash flow per share	-0.20 -	-0.34 67.80%	-1.32 283.66%	-0.97 26.12%	-1.18 21.23%	-1.32 12.35%
gross profit margin
interest coverage					-70.63 -
inventory turnover
long term debt to capitalization			0.01 -	0.00 86.52%	0.49 65,653.80%	0.00 99.69%
net income per ebt	1 -	1 0%	1 0%	0.99 0.55%	0.99 0.67%	1 1.23%
net profit margin
operating cash flow per share	-0.20 -	-0.34 67.35%	-1.31 283.60%	-0.97 26.02%	-1.18 21.15%	-1.32 12.45%
operating profit margin
payables turnover						0.07 -
pretax profit margin
price fair value	-460.62 -	98.54 121.39%	4.21 95.73%	1.22 71.10%	1.17 3.81%	1.13 3.00%
receivables turnover
return on assets	-3.84 -	-1.69 55.84%	-0.29 82.88%	-0.17 42.71%	-0.24 44.01%	-0.37 52.73%
return on capital employed	8.56 -	-2.57 130.09%	-0.30 88.41%	-0.18 41.06%	-0.26 46.50%	-0.44 69.43%
return on equity	8.56 -	-2.57 130.09%	-0.30 88.35%	-0.17 42.72%	-0.25 46.33%	-0.39 55.21%
total debt to capitalization			0.01 -	0.00 47.87%	0.49 16,913.55%	0.01 98.83%

NASDAQ:LTRN

Lantern Pharma Inc.

Last Close

6.33

16/05 20:00

Market Cap

46.63M

Beta: 0.64

Volume Today

44.21K

Avg: 24.91K

PE Ratio

−3.14

PFCF: −3.29